OBJECTIVES : To provide budget impact analysis of secukinumab in the treatment of ankylosing spondylitis by the biological therapy in the Russian Federation.

METHODS : Budget impact analysis of treatment of ankylosing spondylitis was carried out on the for cohort of 100 patients in the Russian Federation. With the current distribution of patients, adalimumab received 26%, golimumab - 14%, infliximab - 26%, etanercept 18%, certolizumab pegol 7%, secukinumab - 9%. With the simulated distribution of patients, the share of the most economical drug, secukinumab, was increased to 21.8%, while the shares of adalimumab, golimumab, infliximab, certolizumab pegol and etanercept were 21.6%, 13.8%, 13.8%, 5, 8%, 13.8%, respectively. Also, in the simulated distribution, the shares of recently registered drugs - netakimab - 6.8%, and ixekizumab - 2.6% were taken into account. Time horizon was 3 years. Exchange rate was 1 euro = 81 RUR.

RESULTS : With the current distribution of patients between drugs the budget was €1 136 527 in the first year and €3 195 382 for three years. With a simulated distribution with increased share of secukinumab, the costs in the first year were €1 069 460 and €2 968 446 for three years. Thus, when calculating per 100 patients, the simulated distribution of patients in comparison with the current one provided savings in the amount of €102 335 in the first year and €226 936 for three years.

CONCLUSIONS : From budget impact analysis perspective increasing share of secukinumab in the treatment of ankylosing spondylitis by the biological therapy provided cost-savings.